All these functional molecules were upregulated in Erlotinib-resistant cells when ARL4C was suppressed and JAK2/STAT5/β-catenin axis was activated (Figure 6D), serving as executors for the malignant behaviors when the EGFR path was blocked in NSCLC cells. This evidence concerns the gene STAT5B and non-small cell lung carcinoma.